Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,056 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis.
Kikuyama R, Fukunaga K, Kawai M, Yokoyama Y, Kamikozuru K, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kato K, Kono T, Nogami K, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Kikuyama R, et al. Among authors: takeda n. Ther Apher Dial. 2011 Aug;15(4):360-6. doi: 10.1111/j.1744-9987.2011.00968.x. Ther Apher Dial. 2011. PMID: 21884470
Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Yokoyama Y, Iimuro M, Takeda N, Kato K, Kikuyama R, Nagase K, Hori K, Nakamura S, Miwa H, Matsumoto T. Yoshida K, et al. Among authors: takeda n. Inflamm Bowel Dis. 2012 Sep;18(9):1617-23. doi: 10.1002/ibd.21928. Epub 2011 Nov 13. Inflamm Bowel Dis. 2012. PMID: 22081474 Clinical Trial.
Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
Fukunaga K, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Fukunaga K, et al. Among authors: takeda n. J Clin Apher. 2011 Dec;26(6):326-31. doi: 10.1002/jca.20314. Epub 2011 Nov 14. J Clin Apher. 2011. PMID: 22083887 Clinical Trial.
Mechanism of carcinogenesis in familial tumors.
Tamura K, Utsunomiya J, Iwama T, Furuyama J, Takagawa T, Takeda N, Fukuda Y, Matsumoto T, Nishigami T, Kusuhara K, Sagayama K, Nakagawa K, Yamamura T. Tamura K, et al. Among authors: takeda n. Int J Clin Oncol. 2004 Aug;9(4):232-45. doi: 10.1007/s10147-004-0430-4. Int J Clin Oncol. 2004. PMID: 15375699 Review.
IL18 polymorphism is associated with an increased risk of Crohn's disease.
Tamura K, Fukuda Y, Sashio H, Takeda N, Bamba H, Kosaka T, Fukui S, Sawada K, Tamura K, Satomi M, Yamada T, Yamamura T, Yamamoto Y, Furuyama J, Okamura H, Shimoyama T. Tamura K, et al. Among authors: takeda n. J Gastroenterol. 2002 Nov;37 Suppl 14:111-6. doi: 10.1007/BF03326428. J Gastroenterol. 2002. PMID: 12572878
Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
Shiba-Ishii A, Isagawa T, Shiozawa T, Mato N, Nakagawa T, Takada Y, Hirai K, Hong J, Saitoh A, Takeda N, Niki T, Murakami Y, Matsubara D. Shiba-Ishii A, et al. Among authors: takeda n. Biochim Biophys Acta Mol Basis Dis. 2024 May 18:167249. doi: 10.1016/j.bbadis.2024.167249. Online ahead of print. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 38768929
2,056 results